PH12016501965A1 - S1p modulator immediate release dosage regimen - Google Patents

S1p modulator immediate release dosage regimen

Info

Publication number
PH12016501965A1
PH12016501965A1 PH12016501965A PH12016501965A PH12016501965A1 PH 12016501965 A1 PH12016501965 A1 PH 12016501965A1 PH 12016501965 A PH12016501965 A PH 12016501965A PH 12016501965 A PH12016501965 A PH 12016501965A PH 12016501965 A1 PH12016501965 A1 PH 12016501965A1
Authority
PH
Philippines
Prior art keywords
immediate release
release dosage
modulator
dosage regimen
siponimod
Prior art date
Application number
PH12016501965A
Other languages
English (en)
Inventor
Legangneux Eric
Wallstroem Erik
Bouillot Philippe Michael Rene
Reynaud Emeric
Dahlke Frank
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12016501965(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PH12016501965A1 publication Critical patent/PH12016501965A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH12016501965A 2014-04-10 2016-10-04 S1p modulator immediate release dosage regimen PH12016501965A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10
PCT/IB2015/052550 WO2015155709A1 (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Publications (1)

Publication Number Publication Date
PH12016501965A1 true PH12016501965A1 (en) 2017-01-09

Family

ID=52988364

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016501965A PH12016501965A1 (en) 2014-04-10 2016-10-04 S1p modulator immediate release dosage regimen

Country Status (17)

Country Link
US (4) US20170027907A1 (cg-RX-API-DMAC10.html)
EP (4) EP3831378A1 (cg-RX-API-DMAC10.html)
JP (1) JP6674903B2 (cg-RX-API-DMAC10.html)
KR (2) KR20220156981A (cg-RX-API-DMAC10.html)
CN (2) CN106456552A (cg-RX-API-DMAC10.html)
AU (2) AU2015246036A1 (cg-RX-API-DMAC10.html)
CA (1) CA2943598C (cg-RX-API-DMAC10.html)
CL (1) CL2016002562A1 (cg-RX-API-DMAC10.html)
ES (1) ES3070843T3 (cg-RX-API-DMAC10.html)
IL (2) IL305337A (cg-RX-API-DMAC10.html)
MX (1) MX2016013245A (cg-RX-API-DMAC10.html)
PH (1) PH12016501965A1 (cg-RX-API-DMAC10.html)
RU (2) RU2020107732A (cg-RX-API-DMAC10.html)
SG (1) SG11201607894RA (cg-RX-API-DMAC10.html)
TW (1) TW201622721A (cg-RX-API-DMAC10.html)
WO (1) WO2015155709A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201606519B (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (cg-RX-API-DMAC10.html) 2014-01-24 2018-02-24
CN106456552A (zh) * 2014-04-10 2017-02-22 诺华股份有限公司 S1p调节剂的立即释放剂量方案
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
WO2019064212A1 (en) * 2017-09-29 2019-04-04 Novartis Ag DOSAGE DIAGRAM OF SIPONIMOD
AU2018343239A1 (en) * 2017-09-29 2020-03-12 Novartis Ag Dosing regimen of siponimod
PT3758708T (pt) * 2018-03-01 2025-02-13 Astrazeneca Ab Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性ｄｐｐ１阻害剤及びその用途
WO2025162472A1 (en) 2024-01-31 2025-08-07 Insmed Incorporated Linear dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20131106T1 (hr) * 2008-12-18 2013-12-20 Novartis Ag Hemifumaratna sol od 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
MX367667B (es) * 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.
US20100160259A1 (en) * 2008-12-22 2010-06-24 Robert Schmouder Dosage regimen for a s1p receptor agonist
EP3831371A1 (en) * 2009-09-29 2021-06-09 Novartis AG Dosage regimen of an s1p receptor modulator
SG191286A1 (en) * 2011-01-07 2013-07-31 Novartis Ag Immunosuppressant formulations
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
CA2852142A1 (en) * 2011-10-21 2013-04-25 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
CN106456552A (zh) * 2014-04-10 2017-02-22 诺华股份有限公司 S1p调节剂的立即释放剂量方案

Also Published As

Publication number Publication date
US20220016076A1 (en) 2022-01-20
EP4778590A2 (en) 2026-07-22
AU2015246036A1 (en) 2016-10-13
ES3070843T3 (es) 2026-06-17
CL2016002562A1 (es) 2017-07-28
MX2016013245A (es) 2017-01-16
CA2943598A1 (en) 2015-10-15
ZA201606519B (en) 2017-11-29
RU2016143979A3 (cg-RX-API-DMAC10.html) 2018-11-12
EP3831378A1 (en) 2021-06-09
JP2017510607A (ja) 2017-04-13
AU2020203107A1 (en) 2020-05-28
EP3129020A1 (en) 2017-02-15
CN116650467A (zh) 2023-08-29
IL247986A0 (en) 2016-11-30
US20190054065A1 (en) 2019-02-21
RU2020107732A (ru) 2020-03-30
EP4074312B1 (en) 2026-02-25
RU2016143979A (ru) 2018-05-14
RU2715734C2 (ru) 2020-03-03
WO2015155709A1 (en) 2015-10-15
JP6674903B2 (ja) 2020-04-01
SG11201607894RA (en) 2016-10-28
KR20160141841A (ko) 2016-12-09
CA2943598C (en) 2023-03-07
TW201622721A (zh) 2016-07-01
EP4074312C0 (en) 2026-02-25
IL305337A (en) 2023-10-01
CN106456552A (zh) 2017-02-22
US20170027907A1 (en) 2017-02-02
US20250041266A1 (en) 2025-02-06
EP4074312A1 (en) 2022-10-19
AU2020203107B2 (en) 2021-10-21
KR20220156981A (ko) 2022-11-28

Similar Documents

Publication Publication Date Title
SG10201806787VA (en) Modulators of complement factor b
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
PH12017500746A1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
PH12017500933A1 (en) Sublingual administration of riluzole
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
MX2016013245A (es) Regimen de dosificacion de liberacion inmediata de moduladores s1p.
EP3141603A4 (en) Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
PH12017500934B1 (en) Sublingual formulation of riluzole
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
MY175326A (en) Product and method for treating diarrhea
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
MX2017000472A (es) Combinacion de extracto de raiz de valeriana y aceite de lavanda para su utilizacion en el tratamiento de trastornos del sueño.
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
NZ709664A (en) Use of fenugreek extract to enhance female libido
PH12017500923A1 (en) New dosage and use of a a2a antagonist
MX2015008454A (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
TR201903234T4 (tr) Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti.
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
EA201491939A1 (ru) Модуляторы прогестероновых рецепторов для применения в профилактике или лечении болезней, опосредованных андрогенами
UA90321U (uk) Спосіб лікування дисбіозу товстої кишки у хворих на віл-інфекцію/снід
UA74055U (ru) Способ хирургического лечения рефрактерных форм глаукомы